TY - JOUR
T1 - The Challenges of Vaccine Trial Participation among Underserved and Hard-to-Reach Communities
T2 - An Internal Expert Consultation of the VACCELERATE Consortium
AU - on behalf of the VACCELERATE Consortium
AU - Poulimeneas, Dimitrios
AU - Koniordou, Markela
AU - Kousi, Dimitra
AU - Merakou, Christina
AU - Kopsidas, Ioannis
AU - Tsopela, Grammatiki Christina
AU - Argyropoulos, Christos D.
AU - Themistocleous, Sophia C.
AU - Shiamakkides, George
AU - Constantinou, Marinos
AU - Alexandrou, Alexandra
AU - Noula, Evgenia
AU - Nearchou, Andria
AU - Salmanton-García, Jon
AU - Stewart, Fiona A.
AU - Heringer, Sarah
AU - Albus, Kerstin
AU - Álvarez-Barco, Elena
AU - Macken, Alan
AU - Di Marzo, Romina
AU - Luis, Catarina
AU - Valle-Simón, Paula
AU - Askling, Helena H.
AU - Hellemans, Margot
AU - Spivak, Orly
AU - Davis, Ruth Joanna
AU - Azzini, Anna Maria
AU - Barta, Imre
AU - Součková, Lenka
AU - Jancoriene, Ligita
AU - Akova, Murat
AU - Mallon, Patrick W.G.
AU - Olesen, Ole F.
AU - Frias-Iniesta, Jesus
AU - van Damme, Pierre
AU - Tóth, Krisztina
AU - Cohen-Kandli, Miriam
AU - Cox, Rebecca Jane
AU - Husa, Petr
AU - Nauclér, Pontus
AU - Marques, Laura
AU - Ochando, Jordi
AU - Tacconelli, Evelina
AU - Zeitlinger, Markus
AU - Cornely, Oliver A.
AU - Pana, Zoi Dorothea
AU - Zaoutis, Theoklis E.
N1 - Publisher Copyright:
© 2023 by the authors.
PY - 2023/12
Y1 - 2023/12
N2 - Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within—and across—countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
AB - Underserved and hard-to-reach population groups are under-represented in vaccine trials. Thus, we aimed to identify the challenges of vaccine trial participation of these groups in member countries of the VACCELERATE network. Seventeen National Coordinators (NC), each representing their respective country (15 European countries, Israel, and Turkey), completed an online survey. From 15 eligible groups, those that were more frequently declared underserved/hard-to-reach in vaccine research were ethnic minorities (76.5%), persons experiencing homelessness (70.6%), illegal workers and refugees (64.7%, each). When prioritization for education on vaccine trials was considered, ethnic groups, migrants, and immigrants (5/17, 29.4%) were the groups most frequently identified by the NC as top targets. The most prominent barriers in vaccine trial participation affecting all groups were low levels of health literacy, reluctance to participate in trials due to engagement level, and low levels of trust in vaccines/vaccinations. This study highlighted population groups considered underserved/hard-to-reach in countries contained within the European region, and the respective barriers these groups face when participating in clinical studies. Our findings aid with the design of tailored interventions (within—and across—countries of the European region) and with the development of strategies to overcome major barriers in phase 2 and phase 3 vaccine trial participation.
KW - barriers
KW - COVID-19
KW - Europe
KW - pandemic preparedness
KW - SARS-CoV-2
KW - vaccinations
KW - vaccine education
KW - vaccine trials
UR - https://www.scopus.com/pages/publications/85180716602
U2 - 10.3390/vaccines11121784
DO - 10.3390/vaccines11121784
M3 - Article
AN - SCOPUS:85180716602
SN - 2076-393X
VL - 11
JO - Vaccines
JF - Vaccines
IS - 12
M1 - 1784
ER -